Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Leigh Turner, Paul S Knoepfler

Research output: Contribution to journalArticle

182 Scopus citations

Abstract

Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

Original languageEnglish (US)
JournalCell Stem Cell
DOIs
StateAccepted/In press - 2016

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine
  • Genetics

Fingerprint Dive into the research topics of 'Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry'. Together they form a unique fingerprint.

  • Cite this